 |
||||||||||
|
|
|
|
|
CLINICAL OUTLOOK
Center for Celiac Research University of Maryland Baltimore, Maryland http://celiaccenter.org/ The Center continues to work with Alba Therapeutics to accelerate our goal to find an alternative treatment/cure for celiac disease. Alba has already completed a clinical trial in celiac patients with preliminary data that were so promising that the FDA approved the next Phase II multi-center trial. Dr. Robert Anderson from Australia has joined the Center for Celiac Research as a visiting faculty member. Dr. Anderson's research focus is a vaccine for celiac disease. In addition, Alessio Fasano, MD was named Entrepreneur of the Year at the University of Maryland. Below is a release from the University. ENTREPRENEUR OF THE YEAR—Alessio Fasano, MD “Discovery is to see what everyone else has seen and to think what no one else has thought.” Those words from 1937 Nobel Prize winner Albert Szent Györgyi enjoy a prominent place in the office of Alessio Fasano, the director of the Mucosal Biology Research Center (MBRC) at the School of Medicine and founder of the Center for Celiac Research, which is housed in the MBRC in Health Sciences Facility II. That sense of discovery, plus rigorous discipline, a little serendipity, and a large dose of luck, is what Fasano—a pediatric gastroenterologist and professor of pediatrics, medicine, and physiology at the School of Medicine—credits with guiding him to some remarkable discoveries and accomplishments. Fasano moved to Baltimore from Naples, Italy, in 1993 with a scholarship to the School of Medicine’s Center for Vaccine Development. In 2000, Fasano and his colleagues discovered zonulin, a protein that regulates the permeability of the intestine. In 2004, Fasano and Blake Paterson, MD, founded Alba Therapeutics Corporation, now headquartered at the UMB BioPark, to transfer the zonulin technology from the lab’s bench top to the patient’s bedside. Fasano resigned as interim chief scientific officer to return to academics full-time. He is now chair of the company’s scientific advisory board. Technology developments from Fasano’s laboratory have resulted in more than 150 patents now held by Alba Therapeutics. The company, named the Maryland Incubator Company of the Year in 2006, has completed clinical and human trials of AT-1001, its lead compound. AT-1001 is targeted toward the treatment of celiac disease and other autoimmune illnesses. |
|||||
|
||||||||||
 |
|
Copyright © 2008 National Foundation for Celiac Awareness. All rights reserved. Created by NetReach ®
The information found on this website is not intended to be a replacement or substitute for professional medical treatment or for professional medical advice relative to a specific medical condition. We urge you to always seek the advice of your physician. There is no replacement for personal medical treatment and advice from your personal physician. This site was last updated on August 25, 2008. If you have questions, please contact webmaster@celiaccentral.org | View Site Map Privacy Policy: NFCA does not share or otherwise disclose any personal information, including your name, address, or email addresses with other organizations. Only NFCA staff has access to personally identifiable information provided by visitors to our site. NFCA will never share information with third parties. |